Dr. Reddy's Laboratories Ltd. (RDY)

35.24
0.35 1.00
NYSE : Health Technology
Prev Close 34.89
Open 34.98
Day Low/High 34.96 / 35.50
52 Wk Low/High 31.58 / 42.82
Volume 164.31K
Avg Volume 183.80K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 5.85B
EPS 1.60
P/E Ratio 21.27
Div & Yield 0.26 (0.82%)
Dr. Reddy’s Announces The USFDA Approval Of Fondaparinux Sodium Injection

Dr. Reddy’s Announces The USFDA Approval Of Fondaparinux Sodium Injection

Dr. Reddy’s Laboratories (NYSE: RDY) and Alchemia Limited, Brisbane, Australia (ASX: ACL) announced today that Dr.

Dr. Reddy's To Release Q1 FY12 Results On July 20, 2011

Dr. Reddy's To Release Q1 FY12 Results On July 20, 2011

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2011 on Wednesday, July 20, 2011, after the Board Meeting.

Dr. Reddy’s Announces The Launch Of Levofloxacin Tablets

Dr. Reddy’s Announces The Launch Of Levofloxacin Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Levofloxacin tablets (250 mg, 500 mg and 750 mg), a bioequivalent generic version of LEVAQUIN ®* tablets in the US market on June...

Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY)

Dr. Reddy Stock To Go Ex-dividend Tomorrow (RDY)

The ex-dividend date for Dr. Reddy Laboratories (NYSE:RDY) is tomorrow, June 14, 2011. Owners of shares as of market close today will be eligible for a dividend of 36 cents per share. At a price of $35 as of 9:31 a.m., the dividend yield is 0.6%.

Dr. Reddy’s Announces Three Generic Product Launches In The US Market

Dr. Reddy’s Announces Three Generic Product Launches In The US Market

Dr. Reddy’s Laboratories (NYSE: RDY) today announced that it has launched the following three products in the US market: Donepezil Hydrochloride tablets (5mg and 10mg strengths), a ...

7 India Stocks With Upside

7 India Stocks With Upside

iGate, ICICI Bank and Patni are expected to deliver up to 49% in the next one year.

Dr. Reddy’s Q4 FY11 & FY11 Financial Results

Dr. Reddy’s Q4 FY11 & FY11 Financial Results

Dr. Reddy’s Laboratories Ltd.

Emerging-Market ADRs: Winners and Losers

Emerging-Market ADRs: Winners and Losers

China's oil and gas stocks and India's banks pulled back sharply at close last week.

Dr. Reddy's To Release Q4 & Full Year FY11 Results On May 13, 2011

Dr. Reddy's To Release Q4 & Full Year FY11 Results On May 13, 2011

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Fourth Quarter & Full Year ended March 31, 2011 on Friday, May 13, 2011 after the Board Meeting.

Dr. Reddy Laboratories Ltd. Stock Upgraded (RDY)

Dr. Reddy Laboratories Ltd. Stock Upgraded (RDY)

Dr. Reddy Laboratories (NYSE:RDY) has been upgraded by TheStreet Ratings from a hold to buy.

5 Pharma Stocks That Could Get Squeezed Higher

5 Pharma Stocks That Could Get Squeezed Higher

These heavily shorted pharmaceutical stocks offer potential short-squeeze opportunities.

Dr. Reddy’s Announces The Launch Of Over-the-Counter Fexofenadine HCl Tablets

Dr. Reddy’s Announces The Launch Of Over-the-Counter Fexofenadine HCl Tablets

Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine HCl tablets on April 13, 2011.

PromiusTM Pharma And Valeant Form Collaboration To Market Cloderm® Cream In The United States

PromiusTM Pharma And Valeant Form Collaboration To Market Cloderm® Cream In The United States

Promius TM Pharma, LLC, an affiliate of Dr. Reddy’s Laboratories (NYSE:RDY), and Valeant Pharmaceuticals International, Inc.

Dr. Reddy’s Announces Completion Of The Acquisition Of US Penicillin Facility And Products From GlaxoSmithKline

Dr. Reddy’s Announces Completion Of The Acquisition Of US Penicillin Facility And Products From GlaxoSmithKline

Dr. Reddy’s Laboratories (NYSE:RDY) today announced the completion of the acquisition of GlaxoSmithKline’s (GSK) United States oral penicillin facility and product portfolio pursuant to the agreement signed and ...

Dr. Reddy’s Launches Levocetirizine Tablets In US

Dr. Reddy’s Launches Levocetirizine Tablets In US

Dr. Reddy’s Laboratories (NYSE:RDY) has launched Levocetirizine tablets (5mg), a bioequivalent generic version of Xyzal® tablets in the US market.

6 Indian Growth Stocks With Upside: Analysts

6 Indian Growth Stocks With Upside: Analysts

HDFC Bank, ICICI Bank and Dr Reddy's are among the Indian stocks that will likely provide an upside up to 31%, according to analysts' estimates.

Dr. Reddy’s Provides Update On The Fexofenadine-Pseudoephedrine 24 Hour Litigation

Dr. Reddy’s Provides Update On The Fexofenadine-Pseudoephedrine 24 Hour Litigation

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that on Friday, 28 January 2011, the U.

Dr. Reddy's Management Discusses Q3 2011 Results - Earnings Call Transcript

Dr. Reddy's Management Discusses Q3 2011 Results - Earnings Call Transcript

Dr. Reddy's Management Discusses Q3 2011 Results - Earnings Call Transcript

Dr. Reddy’s Q3 FY11 Financial Results

Dr. Reddy’s Q3 FY11 Financial Results

Dr. Reddy’s Laboratories Ltd.

5 Drug Stocks With Upside Potential of 25%

5 Drug Stocks With Upside Potential of 25%

These five firms could return 16% to 25% over the next 12 months based on analysts' consensus estimates.

Dr. Reddy's To Release Q3 FY11 Results On January 25, 2011

Dr. Reddy's To Release Q3 FY11 Results On January 25, 2011

Dr. Reddy's Laboratories (NYSE:RDY) will announce results for the Third Quarter ended December 31, 2010 on Tuesday, January 25 th 2011 after the Board Meeting.

Top 10 Emerging Markets Stocks in 2010

Top 10 Emerging Markets Stocks in 2010

These stocks clocked significant gains in 2010, outperforming the broader indices.

GlaxoSmithKline And Dr. Reddy’s Agree To The Sale Of US Penicillin Facility And Products

GlaxoSmithKline And Dr. Reddy’s Agree To The Sale Of US Penicillin Facility And Products

GlaxoSmithKline plc (GSK) and Dr. Reddy’s Laboratories (NYSE:RDY) today announced that the companies have signed an agreement relating to GSK’s United States oral penicillin facility and product portfolio.

Dr. Reddy’s Announces The Launch Of Zafirlukast Tablets

Dr. Reddy’s Announces The Launch Of Zafirlukast Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Zafirlukast tablets (10 mg and 20 mg), a bioequivalent generic version of Accolate® in the US market.

9 Safe India Stocks

9 Safe India Stocks

The following Indian stocks are safe and could deliver substantial appreciation in the long term.

Top 10 Emerging Market Stocks

Top 10 Emerging Market Stocks

A few emerging market ADRs generated lucrative returns for investors during the past one month.

3 Stock Picks to Boost Exposure to India

3 Stock Picks to Boost Exposure to India

Richard Kang, Chief Investment Officer at EG Shares makes the case for investing in India, and offers three Indian investment ideas.

Dr. Reddy’s Q2 FY11 Financial Results

Dr. Reddy’s Q2 FY11 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Announces The Approval Of Lansoprazole Delayed-release Capsules

Dr. Reddy’s Announces The Approval Of Lansoprazole Delayed-release Capsules

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid ®* Delayed-Release ...

TheStreet Quant Rating: B- (Buy)